Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated since fosmetpantotenate did not show statistically significant effects or clinical benefits during the double-blind period.

Conditions

Pantothenate Kinase-Associated Neurodegeneration

Interventions

DRUG: Fosmetpantotenate
DRUG: Placebo

Sponsor

Travere Therapeutics, Inc.